Psychosocial Comorbidities and Health Status Among Adults with Moderate-to-Severe Atopic Dermatitis: A 2017 US National Health and Wellness Survey Analysis.
Anxiety
Atopic dermatitis
Depression
Health-related quality of life
Healthcare resource utilization
Itch
Pruritus
Sleep difficulties
Work impairment
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
16
11
2020
accepted:
15
01
2021
pubmed:
9
2
2021
medline:
15
4
2021
entrez:
8
2
2021
Statut:
ppublish
Résumé
Atopic dermatitis (AD) is associated with sleep difficulties, depression, and anxiety. We evaluated the relationship between these psychosocial comorbidities and health outcomes among adults with moderate-to-severe AD in the USA. Data were analyzed from the 2017 US National Health and Wellness Survey. Respondents with a physician diagnosis of AD or eczema with moderate-to-severe AD based on a Dermatology Life Quality Index score of 6 or more were included. Generalized linear models were used to examine the relationship between psychosocial comorbidities (sleep difficulties and anxiety based on self-report, depression based on the Patient Health Questionnaire-9) and health outcomes [the 36-item Short Form Health Survey, version 2; EuroQol five-dimension, five-level; Work Productivity and Activity Impairment questionnaire; and healthcare resource utilization (HRU)]. Among respondents with moderate-to-severe AD (N = 1017), 56.6%, 70.7%, and 60.9% reported sleep difficulties, depression, and anxiety, respectively. These comorbidities were significantly associated with reduced physical and mental component summary scores and increased overall work impairment (P < 0.05 for all). Increased HRU was also observed. Psychosocial comorbidities were frequently reported by respondents with moderate-to-severe AD and were significantly associated with health status, work loss, and HRU.
Identifiants
pubmed: 33555555
doi: 10.1007/s12325-021-01630-z
pii: 10.1007/s12325-021-01630-z
pmc: PMC7932976
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1627-1637Références
Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10–22.e2.
doi: 10.1016/j.anai.2017.10.039
Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC phase three. J Allergy Clin Immunol. 2009;124(6):1251–8.e23.
doi: 10.1016/j.jaci.2009.10.009
Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132–8.
doi: 10.1016/j.jaci.2013.08.031
Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274–9.e3.
doi: 10.1016/j.jaad.2017.04.019
Yu SH, Attarian H, Zee P, Silverberg JI. Burden of sleep and fatigue in US adults with atopic dermatitis. Dermatitis. 2016;27(2):50–8.
doi: 10.1097/DER.0000000000000161
Yu SH, Silverberg JI. Association between atopic dermatitis and depression in US adults. J Investig Dermatol. 2015;135(12):3183–6.
doi: 10.1038/jid.2015.337
Ronnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(3):448–56.e30.
doi: 10.1016/j.jaad.2018.03.017
Drucker AM, Qureshi AA, Amand C, et al. Health care resource utilization and costs among adults with atopic dermatitis in the United States: a claims-based analysis. J Allergy Clin Immunol Pract. 2018;6(4):1342–8.
doi: 10.1016/j.jaip.2017.10.024
Eichenfield LF, DiBonaventura M, Xenakis J, et al. Costs and treatment patterns among patients with atopic dermatitis using advanced therapies in the United States: analysis of a retrospective claims database. Dermatol Ther (Heidelb). 2020;10(4):791–806.
doi: 10.1007/s13555-020-00413-8
Shrestha S, Miao R, Wang L, Chao J, Yuce H, Wei W. Burden of atopic dermatitis in the United States: analysis of healthcare claims data in the commercial, Medicare, and Medi-Cal databases. Adv Ther. 2017;34(8):1989–2006.
doi: 10.1007/s12325-017-0582-z
Nørreslet LB, Ebbehoj NE, Ellekilde Bonde JP, Thomsen SF, Agner T. The impact of atopic dermatitis on work life—a systematic review. J Eur Acad Dermatol Venereol. 2018;32(1):23–38.
doi: 10.1111/jdv.14523
United States Census Bureau. Current population survey. https://www.census.gov/programs-surveys/cps/data-detail.html . Accessed 25 Mar 2020.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.
doi: 10.1111/j.1365-2230.1994.tb01167.x
Quan H, Li B, Couris CM, Fushimi K, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82.
doi: 10.1093/aje/kwq433
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.
doi: 10.1046/j.1525-1497.2001.016009606.x
Ware J, Kosinski M, Bjorner J, Turner-Bowker D, Gandek B, Maruish M. User's manual for the SF-36v2
Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.
doi: 10.1007/s11136-011-9903-x
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–65.
doi: 10.2165/00019053-199304050-00006
Jeon C, Yan D, Nakamura M, et al. Frequency and management of sleep disturbance in adults with atopic dermatitis: a systematic review. Dermatol Ther (Heidelb). 2017;7(3):349–64.
doi: 10.1007/s13555-017-0192-3
Cheng BT, Silverberg JI. Depression and psychological distress in US adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):179–85.
doi: 10.1016/j.anai.2019.06.002
Silverberg JI, Gelfand JM, Margolis DJ, et al. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in US adults. Br J Dermatol. 2019;181(3):554–65.
doi: 10.1111/bjd.17683
Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Investig Dermatol. 2015;135(1):56–66.
doi: 10.1038/jid.2014.325
Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol. 2018;154(8):903–12.
doi: 10.1001/jamadermatol.2018.1572
Gupta S, Goren A, Kim E, Gabriel S, Dupclay L. Direct and indirect costs of sleep disturbances and residual symptoms in patients treated for depression: analysis of a nationwide cross sectional survey. J Occup Environ Med. 2012;54(7):881–8.
doi: 10.1097/JOM.0b013e31825107da
Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol. 2018;45(2):150–7.
doi: 10.1111/1346-8138.14116
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48.
doi: 10.1056/NEJMoa1610020
Silverberg JI, Patel N, Immaneni S, et al. Assessment of atopic dermatitis using self-report and caregiver report: a multicentre validation study. Br J Dermatol. 2015;173(6):1400–4.
doi: 10.1111/bjd.14031